469 related articles for article (PubMed ID: 26888382)
1. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study.
Azoulay L; Filion KB; Platt RW; Dahl M; Dormuth CR; Clemens KK; Durand M; Juurlink DN; Targownik LE; Turin TC; Paterson JM; Ernst P;
BMJ; 2016 Feb; 352():i581. PubMed ID: 26888382
[TBL] [Abstract][Full Text] [Related]
2. Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis.
Azoulay L; Filion KB; Platt RW; Dahl M; Dormuth CR; Clemens KK; Durand M; Hu N; Juurlink DN; Paterson JM; Targownik LE; Turin TC; Ernst P; ; Suissa S; Dormuth CR; Hemmelgarn BR; Teare GF; Caetano P; Chateau D; Henry DA; Paterson JM; LeLorier J; Levy AR; Ernst P; Platt RW; Sketris IS
JAMA Intern Med; 2016 Oct; 176(10):1464-1473. PubMed ID: 27479930
[TBL] [Abstract][Full Text] [Related]
3. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study.
Abrahami D; Douros A; Yin H; Yu OH; Faillie JL; Montastruc F; Platt RW; Bouganim N; Azoulay L
BMJ; 2018 Dec; 363():k4880. PubMed ID: 30518618
[TBL] [Abstract][Full Text] [Related]
4. Use of incretin agents and risk of pancreatic cancer: a population-based cohort study.
Knapen LM; van Dalem J; Keulemans YC; van Erp NP; Bazelier MT; De Bruin ML; Leufkens HG; Croes S; Neef C; de Vries F; Driessen JH
Diabetes Obes Metab; 2016 Mar; 18(3):258-65. PubMed ID: 26537555
[TBL] [Abstract][Full Text] [Related]
5. Incretin-based Drugs and the Incidence of Colorectal Cancer in Patients with Type 2 Diabetes.
Abrahami D; Yin H; Yu OHY; Pollak MN; Azoulay L
Epidemiology; 2018 Mar; 29(2):246-253. PubMed ID: 29283894
[TBL] [Abstract][Full Text] [Related]
6. Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study.
Ueda P; Wintzell V; Melbye M; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Svanström H; Pasternak B
Diabetologia; 2021 Oct; 64(10):2204-2214. PubMed ID: 34254177
[TBL] [Abstract][Full Text] [Related]
7. Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study.
Faillie JL; Azoulay L; Patenaude V; Hillaire-Buys D; Suissa S
BMJ; 2014 Apr; 348():g2780. PubMed ID: 24764569
[TBL] [Abstract][Full Text] [Related]
8. Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study.
Gokhale M; Buse JB; Gray CL; Pate V; Marquis MA; Stürmer T
Diabetes Obes Metab; 2014 Dec; 16(12):1247-56. PubMed ID: 25109825
[TBL] [Abstract][Full Text] [Related]
9. Does the use of incretin-based medications increase the risk of cancer in patients with type-2 diabetes mellitus?
Karp I; Sivaswamy A; Booth C
Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):489-499. PubMed ID: 30779266
[TBL] [Abstract][Full Text] [Related]
10. Incretin-based pharmacotherapy and risk of adverse pancreatic events in the ethnic Chinese with diabetes mellitus: A population-based study in Taiwan.
Tseng CM; Liao WC; Chang CY; Lee CT; Tseng CH; Hsu YC; Lin JT
Pancreatology; 2017; 17(1):76-82. PubMed ID: 27743712
[TBL] [Abstract][Full Text] [Related]
11. Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study.
Knapen LM; de Jong RG; Driessen JH; Keulemans YC; van Erp NP; De Bruin ML; Leufkens HG; Croes S; de Vries F
Diabetes Obes Metab; 2017 Mar; 19(3):401-411. PubMed ID: 27883260
[TBL] [Abstract][Full Text] [Related]
12. Incretin-based drugs and the risk of congestive heart failure.
Yu OH; Filion KB; Azoulay L; Patenaude V; Majdan A; Suissa S
Diabetes Care; 2015 Feb; 38(2):277-84. PubMed ID: 25205143
[TBL] [Abstract][Full Text] [Related]
13. Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
Wang H; Liu Y; Tian Q; Yang J; Lu R; Zhan S; Haukka J; Hong T
Diabetes Obes Metab; 2018 Apr; 20(4):910-920. PubMed ID: 29193572
[TBL] [Abstract][Full Text] [Related]
14. Incretin-based drugs and risk of lung cancer among individuals with type 2 diabetes.
Rouette J; Yin H; Yu OHY; Bouganim N; Platt RW; Azoulay L
Diabet Med; 2020 May; 37(5):868-875. PubMed ID: 32124472
[TBL] [Abstract][Full Text] [Related]
15. A Multicenter Observational Study of Incretin-based Drugs and Heart Failure.
Filion KB; Azoulay L; Platt RW; Dahl M; Dormuth CR; Clemens KK; Hu N; Paterson JM; Targownik L; Turin TC; Udell JA; Ernst P;
N Engl J Med; 2016 Mar; 374(12):1145-54. PubMed ID: 27007958
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study.
Abrahami D; Douros A; Yin H; Yu OHY; Renoux C; Bitton A; Azoulay L
BMJ; 2018 Mar; 360():k872. PubMed ID: 29563098
[TBL] [Abstract][Full Text] [Related]
17. Nationwide Trends in Pancreatitis and Pancreatic Cancer Risk Among Patients With Newly Diagnosed Type 2 Diabetes Receiving Dipeptidyl Peptidase 4 Inhibitors.
Lee M; Sun J; Han M; Cho Y; Lee JY; Nam CM; Kang ES
Diabetes Care; 2019 Nov; 42(11):2057-2064. PubMed ID: 31431452
[TBL] [Abstract][Full Text] [Related]
18. Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes.
Garry EM; Buse JB; Lund JL; Pate V; Stürmer T
Diabetes Obes Metab; 2018 Jan; 20(1):129-140. PubMed ID: 28661561
[TBL] [Abstract][Full Text] [Related]
19. Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus.
Faillie JL; Yu OH; Yin H; Hillaire-Buys D; Barkun A; Azoulay L
JAMA Intern Med; 2016 Oct; 176(10):1474-1481. PubMed ID: 27478902
[TBL] [Abstract][Full Text] [Related]
20. Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink.
Gamble JM; Chibrikov E; Midodzi WK; Twells LK; Majumdar SR
BMJ Open; 2018 Oct; 8(10):e023830. PubMed ID: 30297350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]